J&J files injectable once-monthly Invega in EU for schizophrenia
This article was originally published in Scrip
Executive Summary
Johnson & Johnson has submitted a marketing application to the European Medicines Agency(EMA; formerly EMEA) for its once-monthly injectable version of its oral antipsychotic Invega (paliperidone palmitate) for the treatment of schizophrenia.